Business
Encoded Therapeutics Highlights Progress in Dravet Syndrome Program and Pipeline Ahead of Company Presentation at 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., January 08, 2026--Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today provided an update on the significant progress made during 2025 with its Dravet syndrome candidate, ETX101, including an overview of the positive interim Phase 1/2 clinical results announced last month, establishment of GMP manufacturing capabilities to support its pipeline of gene therapies, and progres
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1496,"height":419,"url":"https://media.zenfs.com/en/business-wire.com/e5952c3d6e64567ee69679003a017d3e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/K97i_BpMw7rtjx6DBgtKhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e5952c3d6e64567ee69679003a017d3e","width":960,"height":269},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gBgay2A5IQerP_11dpu7zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e5952c3d6e64567ee69679003a017d3e","width":1200,"height":336}},"lazy":false},{"type":"text","content":"– Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –","length":135,"tagName":"p","attribs":{}},{"type":"text","content":"– Internal GMP manufacturing capable of supporting pivotal trial and commercialization of ETX101 and gene therapy pipeline –","length":124,"tagName":"p","attribs":{}},{"type":"text","content":"– CEO Kartik Ramamoorthi, Ph.D. to present corporate overview at J.P. Morgan Healthcare Conference –","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 08, 2026--(BUSINESS WIRE)--Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today provided an update on the significant progress made during 2025 with its Dravet syndrome candidate, ETX101, including an overview of the positive interim Phase 1/2 clinical results announced last month, establishment of GMP manufacturing capabilities to support its pipeline of gene therapies, and progress across its overall pipeline.","length":557,"tagName":"p"},{"type":"text","content":""Last year marked a period of significant execution for Encoded, including meaningful progress across our pipeline and manufacturing capabilities. Data that were recently presented at the American Epilepsy Society Annual Meeting underscore the potential clinical impact of ETX101 for people with Dravet syndrome. With our highly experienced team and an operational GMP manufacturing facility we are well-positioned to initiate a pivotal trial...